Abstract:Protein replacement therapy for hemophilia A is very costly and has a potential side effect of developing inhibitors. Gene therapy, on the other hand, can potentially prevent these limitations of current treatments. Although recombinant adeno_associated virus (rAAV) vectors are promising for delivering factor VIII gene, applying AAV vector technology to Hemophilia A lagged behind other genetic diseases because of this size constraint (limited to ∼5kb). Dual AAV vectors have been developed to deliver large genes. Current strategy utlilizing intron mediated DNA concatemerization is inefficient because it is limited by the amount of input rAAV genomes. To overcome this limitation, we have developed a novel strategy to split factor VIII gene into two halves. The split factor VIII genes can then be packaged into two AAV vectors independently along with their own promoters and poly A sequences. Because Intein mediated trans splicing reaction is an autocatalytic reaction which does not require other cellular enzymes and cofactors, intein mediated factor VIII regeneration is highly efficent. When the plasmids containing intein split factor VIII gene were transfected into 293 or COS cells, single chain factor VIII were detected by Western Blot. Hydrodynamic injection of these plasmids into hemophilia mouses led to the correction of aPTT time to the normal level. The amount of functional factor VIII expression reached 3_6 units/ml at peak. The specific activity of factor VIII secreted was about half of B_domain deleted factor VIII plasmid level, which is about 5 fold better than the strategy expressing factro VIII heavy chain and light chain separately. We conclude that intein based factor VIII expressing system uses amplified translation products as the substrate, which is the key to its enhanced performance over the intron mediated dual vector systems. Intein_split factor VIII gene was also utilized for studing factor VIII secretion. By spliting factor VIII genes at various positions, we investigated the role of factor VIII light chain in factor VIII secretion. Without light chain elements, factor VIII heavy chain was about 100 fold less efficient in secretion. This is the main reason causing the chain imbalance for the strategy expressing the heavy chain and the light chain separately.The effect of light chain in facilicating heavy chain secretion can only function in cis. Further analysis of factor VIII mutants suggested that elements in A3 domain were essential for factor VIII secretion while the sequences in the C_terminus of factor were dispensible. These results led to the improved the heavy chain expression vector. The performance of these novel AAV_FVIII expression vectors is currently evaluated in the hemophilia mouse model.

Rapid establishment of a HEK 293 cell line expressing FVIII-BDD using AAV site-specific integration plasmids

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Construction Of A Novel Lentiviral Vector Carrying Human B-Domain-Deleted Factor Viii Gene

High Level Expression of Human Factor VIII in Mammalian Cells after Retroviral-Mediated Gene Transfer.

Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system

Development of inducible packaging cell line for rAAV production via CRISPR-Cas9 mediated site-specific integration

Modified expi293 cell culture system using piggyBac transposon enables efficient production of human FVIII

[Effective and Stable in Vitro Expression of Human Coagulation Factor VIII by Retrovirus-Based Plasmid Vector Coupled with Polyamidoamine Dendrimer].

Efficient Production of Dual Recombinant Adeno-Associated Viral Vectors for Factor VIII Delivery.

857. Molecular Engineering of Factor VIII for Raav Delivery

Preparation of A Recombinant Adeno-Associated Viral Vector with A Mutation of Human Factor Ix in Large Scale and Its Expression in Vitro and in Vivo

Preparation of Raav/hflx by HSV/AAV Hybrid Helper Virus and Evaluation of Its Safety

[Non-Viral Vector Mediating Human Coagulation Factor VIII Gene Expression in Mouse 32D Cell Line].

Establishment of A Recombinant Adeno-Associated Virus Expressing Hvegf(165)

Construction of Recombinant Adeno-Associated Virus Vector Co-Expressing Hvegf165 and Hbmp7 Gene

Enhanced factor VIII heavy chain for gene therapy of hemophilia A.

Identification of Activity Enhancement Residue of Human FVIII and Novel Factor VIII Variant for Human Gene Therapy

Gene Therapy for Hemophilia B with Liver-specific Element Mediated by Rep-RBE Site-specific Integration System

Improvement in the suspension-culture production of recombinant adeno-associated virus-LacZ in HEK-293 cells using polyethyleneimine-DNA complexes in combination with hypothermic treatment.

Evaluation of the Activity Levels of Rat FVIII and Human FVIII Delivered by Adeno-Associated Viral Vectors Both in Vitro and in Vivo.

[In Vivo Transfection and Expression of Human Coagulant Factor VIII Cdna in Mice].